| P50 | author | Maria Luisa Cañadas | Q76402484 |
| | Enrique Jiménez-Varo | Q85491076 |
| P2093 | author name string | Cristina Pérez-Ramírez | |
| | María José Faus-Dáder | |
| | Miguel Ángel Calleja-Hernández | |
| P2860 | cites work | The Hallmarks of Cancer | Q221226 |
| | KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib | Q21563446 |
| | Plexins are a large family of receptors for transmembrane, secreted, and GPI-anchored semaphorins in vertebrates | Q22010646 |
| | An integrated map of genetic variation from 1,092 human genomes | Q22122153 |
| | Crystal structure of the HGF beta-chain in complex with the Sema domain of the Met receptor | Q24294589 |
| | Regulation of the Met receptor-tyrosine kinase by the protein-tyrosine phosphatase 1B and T-cell phosphatase | Q24316395 |
| | A family of transmembrane proteins with homology to the MET-hepatocyte growth factor receptor | Q24318269 |
| | A Grb2-associated docking protein in EGF- and insulin-receptor signalling | Q24321653 |
| | Hepatocyte growth factor receptor tyrosine kinase met is a substrate of the receptor protein-tyrosine phosphatase DEP-1 | Q24329131 |
| | Slug regulates integrin expression and cell proliferation in human epidermal keratinocytes | Q24337235 |
| | The Gab1 PH domain is required for localization of Gab1 at sites of cell-cell contact and epithelial morphogenesis downstream from the met receptor tyrosine kinase | Q24554529 |
| | Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197 | Q24608143 |
| | MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib | Q24646295 |
| | Somatic mutations affect key pathways in lung adenocarcinoma | Q24648102 |
| | Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases | Q27657708 |
| | Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK) | Q27671432 |
| | MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling | Q27851406 |
| | Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors | Q27851633 |
| | Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification | Q27851651 |
| | Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial | Q27851712 |
| | Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma | Q27851979 |
| | Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. | Q27852316 |
| | A genetic model for colorectal tumorigenesis | Q27860582 |
| | Cancer statistics, 2014 | Q27861018 |
| | Sustained recruitment of phospholipase C-gamma to Gab1 is required for HGF-induced branching tubulogenesis | Q28139783 |
| | Met receptor tyrosine kinase: enhanced signaling through adapter proteins | Q28140219 |
| | Signaling of hepatocyte growth factor/scatter factor (HGF) to the small GTPase Rap1 via the large docking protein Gab1 and the adapter protein CRKL | Q28141139 |
| | c-Met: structure, functions and potential for therapeutic inhibition | Q28190143 |
| | Cbl-CIN85-endophilin complex mediates ligand-induced downregulation of EGF receptors | Q28207179 |
| | Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations | Q38405477 |
| | Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. | Q38409218 |
| | KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer | Q38432430 |
| | Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival | Q38441644 |
| | NPS-1034, a novel MET inhibitor, inhibits the activated MET receptor and its constitutively active mutants | Q38445359 |
| | S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab | Q39134353 |
| | Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth | Q39472261 |
| | Neuropilin-1 promotes human glioma progression through potentiating the activity of the HGF/SF autocrine pathway | Q39819576 |
| | Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. | Q39916367 |
| | Regulation of scatter factor/hepatocyte growth factor responses by Ras, Rac, and Rho in MDCK cells | Q40021756 |
| | Direct repression of cyclin D1 by SIP1 attenuates cell cycle progression in cells undergoing an epithelial mesenchymal transition. | Q40080958 |
| | Somatic mutations lead to an oncogenic deletion of met in lung cancer | Q40333112 |
| | Cigarette smoking induces overexpression of hepatocyte growth factor in type II pneumocytes and lung cancer cells | Q40357175 |
| | Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition | Q40360895 |
| | Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. | Q40382332 |
| | Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. | Q40453775 |
| | Grb2-independent recruitment of Gab1 requires the C-terminal lobe and structural integrity of the Met receptor kinase domain | Q40645288 |
| | Crk synergizes with epidermal growth factor for epithelial invasion and morphogenesis and is required for the met morphogenic program | Q40715731 |
| | A novel germ line juxtamembrane Met mutation in human gastric cancer | Q40847293 |
| | Involvement of Cdc42 small G protein in cell-cell adhesion, migration and morphology of MDCK cells | Q40937421 |
| | Differential signaling by alternative HGF isoforms through c-Met: activation of both MAP kinase and PI 3-kinase pathways is insufficient for mitogenesis | Q40949581 |
| | Tyrosine phosphorylation of focal adhesion kinase stimulated by hepatocyte growth factor leads to mitogen-activated protein kinase activation | Q41007034 |
| | Branching tubulogenesis but not scatter of madin-darby canine kidney cells requires a functional Grb2 binding site in the Met receptor tyrosine kinase | Q41168656 |
| | Hepatocyte growth factor-induced scatter of Madin-Darby canine kidney cells requires phosphatidylinositol 3-kinase. | Q41270218 |
| | The HGF receptor family: unconventional signal transducers for invasive cell growth | Q41458148 |
| | Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth | Q41596252 |
| | MET amplification status in therapy-naïve adeno- and squamous cell carcinomas of the lung | Q41709286 |
| | A novel recognition motif for phosphatidylinositol 3-kinase binding mediates its association with the hepatocyte growth factor/scatter factor receptor | Q41879451 |
| | Paracrine regulation of germinal center B cell adhesion through the c-met-hepatocyte growth factor/scatter factor pathway | Q41903686 |
| | Scatter factor/hepatocyte growth factor and its receptor, the c-met tyrosine kinase, can mediate a signal exchange between mesenchyme and epithelia during mouse development | Q42770153 |
| | Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer | Q42780600 |
| | Novel mutations of the MET proto-oncogene in papillary renal carcinomas. | Q42815807 |
| | A switch from p130Cas/Crk to Gab1/Crk signaling correlates with anchorage independent growth and JNK activation in cells transformed by the Met receptor oncoprotein | Q42832806 |
| | Down-regulation of MET, the receptor for hepatocyte growth factor. | Q43649368 |
| | Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial | Q43658480 |
| | Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). | Q44701539 |
| | Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib | Q45265090 |
| | Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas | Q45345804 |
| | Molecular cloning of a new transforming gene from a chemically transformed human cell line. | Q45345810 |
| | Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer | Q46585170 |
| | Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis | Q47680928 |
| | Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer | Q47992122 |
| | Gene structure of the human MET proto-oncogene | Q48043819 |
| | The endophilin-CIN85-Cbl complex mediates ligand-dependent downregulation of c-Met | Q28207199 |
| | Met, metastasis, motility and more | Q28235183 |
| | Factors underlying sensitivity of cancers to small-molecule kinase inhibitors | Q28252845 |
| | Induction of epithelial tubules by growth factor HGF depends on the STAT pathway | Q28259695 |
| | The Met tyrosine kinase receptor in development and cancer | Q28263626 |
| | A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family | Q28285975 |
| | Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase | Q28286701 |
| | Uncoupling of Grb2 from the Met receptor in vivo reveals complex roles in muscle development | Q28295203 |
| | Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible for epithelial morphogenesis | Q28295920 |
| | Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor | Q28307227 |
| | Scatter factor/hepatocyte growth factor is essential for liver development | Q28504542 |
| | Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud | Q28506228 |
| | Coupling of Gab1 to c-Met, Grb2, and Shp2 mediates biological responses | Q28513246 |
| | Contact inhibition of hepatocyte growth regulated by functional association of the c-Met/hepatocyte growth factor receptor and LAR protein-tyrosine phosphatase | Q28577402 |
| | Lung cancer | Q29615473 |
| | Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer | Q29615476 |
| | Screening for epidermal growth factor receptor mutations in lung cancer | Q29619696 |
| | Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial | Q29619975 |
| | Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study | Q29620648 |
| | Identification of an atypical Grb2 carboxyl-terminal SH3 domain binding site in Gab docking proteins reveals Grb2-dependent and -independent recruitment of Gab1 to receptor tyrosine kinases | Q30168876 |
| | Activation of the JNK pathway is essential for transformation by the Met oncogene | Q30176542 |
| | The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma | Q30494514 |
| | Src homology 2-containing inositol 5-phosphatase 1 binds to the multifunctional docking site of c-Met and potentiates hepatocyte growth factor-induced branching tubulogenesis. | Q31538849 |
| | The human hepatocyte growth factor receptor gene: complete structural organization and promoter characterization | Q32053890 |
| | Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. | Q33345025 |
| | Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group | Q33348775 |
| | The tyrosine phosphatase SHP-2 is required for sustained activation of extracellular signal-regulated kinase and epithelial morphogenesis downstream from the met receptor tyrosine kinase | Q33605698 |
| | Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer | Q33607176 |
| | HGF: a multifunctional growth factor controlling cell scattering. | Q33821093 |
| | The hepatocyte growth factor/Met pathway in development, tumorigenesis, and B-cell differentiation. | Q33922881 |
| | Developing c-MET pathway inhibitors for cancer therapy: progress and challenges | Q34089725 |
| | Met/Hepatocyte growth factor receptor ubiquitination suppresses transformation and is required for Hrs phosphorylation | Q34097397 |
| | New driver mutations in non-small-cell lung cancer | Q34161395 |
| | Durable Response to Crizotinib in a MET-Amplified, KRAS-Mutated Carcinoma of Unknown Primary | Q34181172 |
| | Interaction with the phosphotyrosine binding domain/phosphotyrosine interacting domain of SHC is required for the transforming activity of the FLT4/VEGFR3 receptor tyrosine kinase | Q34384347 |
| | Mutation of juxtamembrane tyrosine residue 1001 suppresses loss-of-function mutations of the met receptor in epithelial cells. | Q34482678 |
| | Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence | Q34555510 |
| | Structural basis of hepatocyte growth factor/scatter factor and MET signalling | Q34572895 |
| | An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms | Q34625881 |
| | Activation of cdc42, rac, PAK, and rho-kinase in response to hepatocyte growth factor differentially regulates epithelial cell colony spreading and dissociation | Q34712138 |
| | Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay | Q34762839 |
| | Cbl-transforming variants trigger a cascade of molecular alterations that lead to epithelial mesenchymal conversion | Q34764852 |
| | Showering c-MET-dependent cancers with drugs | Q34769397 |
| | Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer | Q35010777 |
| | Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer | Q35043706 |
| | Crk associates with a multimolecular Paxillin/GIT2/beta-PIX complex and promotes Rac-dependent relocalization of Paxillin to focal contacts | Q35161063 |
| | Escape from Cbl-mediated downregulation: a recurrent theme for oncogenic deregulation of receptor tyrosine kinases | Q35169572 |
| | c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases | Q35199181 |
| | MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib | Q35666332 |
| | Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer | Q36128435 |
| | Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. | Q36140332 |
| | An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance | Q36597042 |
| | Activation of both MAP kinase and phosphatidylinositide 3-kinase by Ras is required for hepatocyte growth factor/scatter factor-induced adherens junction disassembly | Q36899460 |
| | Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers | Q36905639 |
| | Expression and mutational analysis of MET in human solid cancers | Q36975055 |
| | MET as a target for treatment of chest tumors | Q37232416 |
| | MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. | Q37321772 |
| | MET receptor tyrosine kinase as a therapeutic anticancer target | Q37356047 |
| | Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair | Q37357884 |
| | Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. | Q37398636 |
| | Ethnic differences and functional analysis of MET mutations in lung cancer | Q37399540 |
| | Scatter factor/hepatocyte growth factor as a regulator of skeletal muscle and neural crest development | Q37559652 |
| | MET signalling: principles and functions in development, organ regeneration and cancer | Q37811895 |
| | Targeting MET in cancer: rationale and progress | Q37978193 |
| | ALK inhibitors in the treatment of advanced NSCLC. | Q38127953 |
| | Targeting the MET gene for the treatment of non-small-cell lung cancer | Q38172700 |
| | The Met receptor tyrosine kinase: a key player in oncogenesis and drug resistance | Q38175267 |
| P433 | issue | 6 | |
| P921 | main subject | biomarker | Q864574 |
| P304 | page(s) | 631-647 | |
| P577 | publication date | 2015-04-20 | |
| P1433 | published in | Pharmacogenomics | Q15724625 |
| P1476 | title | MET: a new promising biomarker in non-small-cell lung carcinoma | |
| P478 | volume | 16 | |